Abiraterone Acetate Archives - Medical Conferences

Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer

Presented By

Prof. Neil Fleshner, Princess Margaret Cancer Centre, Canada

Trial

Phase 2, ACDC-RP

Conference

ASCO GU 2022

8 April, 2022 11:22

Addition of abiraterone to ADT/docetaxel does not increase bone loss

Presented By

Dr Guilhem Roubaud, Institut Bergonié, France

Trial

Phase 3, PEACE-1

Conference

ASCO GU 2022

8 April, 2022 11:21

Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment

Trial

Phase 3, PEACE-1, STAMPEDE, ARCHES

Conference

ESMO 2021

19 November, 2021 09:27

Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC

Presented By

Prof. Karim Fizazi, University of Paris-Saclay, Villejuif, France

Trial

Phase 3, PEACE-1

Conference

EAU 2021

31 August, 2021 12:15

Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC

Presented By

Dr Karim Fizazi , Institut Gustav Roussy, France

Trial

Phase 3, PEACE-1

Conference

ASCO 2021

12 August, 2021 22:19

Apalutamide prolongs progression-free survival in prostate cancer

Presented By

Dr Dana Rathkopf, Memorial Sloan Kettering Cancer Center, New York, USA

Trial

Phase 3, ACIS

Conference

ASCO GU 2021

24 March, 2021 14:49

Abiraterone in M1 hormone-naïve prostate cancer

Conference

ESMO 2020

25 November, 2020 14:51

New treatment option for patients with mCRPC

Conference

ESMO 2020

25 November, 2020 14:50